1
|
Lonsdorf AS, Enk AH, Hartmann J. Patterns of photoprotective behavior, cumulative sun-exposure and skin cancer risk among solid organ transplant recipients: a dermatology transplant clinic experience. Eur J Cancer Prev 2023; 32:155-162. [PMID: 35671255 DOI: 10.1097/cej.0000000000000751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND The risk for keratinocyte cancer is dramatically increased in solid organ transplant recipients (OTR) with a first post-transplant keratinocyte cancer conferring a high risk for subsequent keratinocyte cancer arising with accelerated dynamics. Despite cumulative ultraviolet radiation (UVR) being the primary responsible environmental carcinogen reduced compliance with photoprotective measures among OTR has been reported. Risk assessment tools could help guide clinical decision-making and targeted prevention strategies for patients at particularly high risk for post-transplant keratinocyte cancer. OBJECTIVES To evaluate cumulative sun exposure by means of an assigned total sun burden (TSB) score, sunscreen use and associated risk factors for keratinocyte cancer in the post-transplantation phase of OTR. METHODS A retrospective single-center cohort study analyzing medical records and standardized questionnaires of 290 OTR cared for at a German dermatology transplant clinic. RESULTS Significantly lower TSB scores were noted in OTR not developing a first keratinocyte cancer compared to OTR developing keratinocyte cancer during their follow-up period ( P = 0.005). Regression analysis assigned a significantly higher risk for the development of first keratinocyte cancer to OTR with TSB scores >10. In total 70.7% of OTR with a history of ≥1 keratinocyte cancer reported intermittent sunscreen use, while daily sunscreen use was overall associated with female gender (21.3%) and age >30 years (17.6%). CONCLUSIONS The risk of OTR for developing keratinocyte cancer is reflected by their UV-exposure patterns, which may be assessed by the TSB-score, a scored risk assessment tool. Complementing clinical data, the TSB score may help clinicians to identify OTR at particularly high risk for keratinocyte cancer and to endorse intensified prevention strategies and dermato-oncologic care.
Collapse
Affiliation(s)
- Anke S Lonsdorf
- Department of Dermatology, Ruprecht-Karls-University of Heidelberg
- Skin Cancer Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany
| | - Alexander H Enk
- Department of Dermatology, Ruprecht-Karls-University of Heidelberg
- Skin Cancer Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany
| | - Julia Hartmann
- Department of Dermatology, Ruprecht-Karls-University of Heidelberg
| |
Collapse
|
2
|
Veldhuizen IJ, Schroen E, Lee EH, Kurtansky NR, Dusza SW, van der Hulst RRWJ, Pusic AL, Hoogbergen MM. Sun Protection Behavior Following Skin Cancer Resection and Reconstruction. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2022; 37:1401-1406. [PMID: 33611743 DOI: 10.1007/s13187-021-01971-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 02/07/2021] [Indexed: 06/12/2023]
Abstract
Increased exposure to ultraviolet radiation (UVR) is associated with an increased risk of nonmelanoma skin cancer. Cutaneous surgery can be negatively influenced by UVR, causing delayed wound healing, hyperpigmentation of the scar, and an increased incidence of additional skin cancers. By changing sun protection behavior, these risks can be limited. Therefore, this study evaluates changes in patients' sun protective behavior after Mohs micrographic surgery (MMS). Patients undergoing MMS between December 2017 and November 2019 were included. Patients were asked to complete the FACE-Q Skin Cancer - Sun Protection Behavior checklist before and 3 months and 1 year post-surgery. A total of 125 patients completed the pre-operative and 3-months post-operative checklists, and 89 (71.2%) completed the 1-year post-operative checklist. Reported sun protective behaviors increased post-surgery at all time points (p < 0.001). Patients with a prior history of facial skin cancer demonstrated a larger increase in sun protection behaviors after surgery than patients without a history of facial skin cancer (p = 0.04). Patients with defects located on the ear or scalp demonstrated a lesser increase in sun protection behaviors than patients with defects located in more conspicuous areas as the face (p = 0.02). Our study demonstrates a change in sun protection behavior, with an increase in sun protection behavior over time in patients after MMS. However, more improvement is possible. Targeted counseling can increase sun protection behavior in patients without a history of facial skin cancer and patients with skin cancer located on the ears or scalp.
Collapse
Affiliation(s)
- I J Veldhuizen
- Department of Plastic and Reconstructive Surgery, Catharina Hospital, Eindhoven, the Netherlands
- Dermatology Division, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Plastic and Reconstructive Surgery, Nutrim, Maastricht University Medical Center, Maastricht, the Netherlands
| | - E Schroen
- Department of Plastic and Reconstructive Surgery, Catharina Hospital, Eindhoven, the Netherlands
| | - E H Lee
- Dermatology Division, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - N R Kurtansky
- Dermatology Division, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - S W Dusza
- Dermatology Division, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - R R W J van der Hulst
- Department of Plastic and Reconstructive Surgery, Nutrim, Maastricht University Medical Center, Maastricht, the Netherlands
| | - A L Pusic
- Plastic and Reconstructive Surgery Division, Brigham and Women's Hospital, Boston, MA, USA
| | - M M Hoogbergen
- Department of Plastic and Reconstructive Surgery, Catharina Hospital, Eindhoven, the Netherlands.
| |
Collapse
|
3
|
Assessing individual patients’ knowledge of benign versus malignant skin lesions in the dermatology clinic population. Int J Womens Dermatol 2022; 8:e032. [PMID: 35923587 PMCID: PMC9324629 DOI: 10.1097/jw9.0000000000000032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Accepted: 06/01/2022] [Indexed: 11/26/2022] Open
Abstract
Skin cancer education targeted to patients’ needs is a goal of practicing dermatologists. Data regarding dermatology patients’ baseline knowledge regarding skin cancer could aid clinicians in tailoring education efforts.
Collapse
|
4
|
Keratinocyte Carcinoma Mortality in the United States as Reported in Death Certificates, 2011-2017. Dermatol Surg 2021; 46:1135-1140. [PMID: 31702593 DOI: 10.1097/dss.0000000000002261] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKROUND Keratinocyte carcinoma (KC) mortality is relatively modest and its measures are subject to considerable error. Deaths due to KC have been decreasing through 2000 and were relatively stable until 2010. OBJECTIVE To estimate the KC mortality rates (MRs) from 2011 to 2017 in USA based on death certificates. METHODS A population-based analysis of Center of Disease Control and Prevention data. Main outcomes and measures were the age-adjusted (US 2000 standard population) MRs. RESULTS Overall, KC MRs increased significantly (b = 0.04, p < .01). For the period studied, KC MR was 1.24 per 100,000 persons per year (0.62 for sun-exposed sites, 0.38 for genital and 0.23 for perianal sites). At sun-exposed genital and perianal anatomic sites, KC MRs have been increasing in whites, but not in blacks. CONCLUSION There was a 17% decrease in the KC MRs until 2000, followed by an increase of 44% through 2017. The accuracy of KC MRs is uncertain. If indeed the increase in mortality is verified, causes may include an increase in KC incidence, an increase of immunosuppressed populations, and changes in the cause of death documentation.
Collapse
|
5
|
Goldenberg A, Vujic I, Sanlorenzo M, Ortiz-Urda S. Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox. Clin Cosmet Investig Dermatol 2015; 8:423-9. [PMID: 26346576 PMCID: PMC4531028 DOI: 10.2147/ccid.s87645] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Introduction Melanoma is the most deadly type of skin cancer with 75% of all skin cancer deaths within the US attributed to it. Risk factors for melanoma include ultraviolet exposure, genetic predisposition, and phenotypic characteristics (eg, fair skin and blond hair). Whites have a 27-fold higher incidence of melanoma than African-Americans (AA), but the 5-year survival is 17.8% lower for AA than Whites. It is reported continuously that AA have more advanced melanomas at diagnosis, and overall lower survival rates. This minority melanoma paradox is not well understood or studied. Objective To explore further, the possible explanations for the difference in melanoma severity and survival in AA within the US. Methods Qualitative review of the literature. Results Lack of minority-targeted public education campaigns, low self-risk perception, low self-skin examinations, intrinsic virulence, vitamin D differences, and physician mistrust may play a role in the melanoma survival disparity among AA. Conclusion Increases in public awareness of melanoma risk among AA through physician and media-guided education, higher index of suspicion among individuals and physicians, and policy changes can help to improve early detection and close the melanoma disparity gap in the future.
Collapse
Affiliation(s)
- Alina Goldenberg
- Department of Internal Medicine/Dermatology, University of California, San Diego, CA, USA
| | - Igor Vujic
- Mt Zion Cancer Research Center, University of California San Francisco, San Francisco, CA, USA ; Department of Dermatology, The Rudolfstiftung Hospital, Academic Teaching Hospital, Medical University Vienna, Vienna, Austria
| | - Martina Sanlorenzo
- Mt Zion Cancer Research Center, University of California San Francisco, San Francisco, CA, USA ; Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Susana Ortiz-Urda
- Mt Zion Cancer Research Center, University of California San Francisco, San Francisco, CA, USA
| |
Collapse
|
6
|
Santiago-Rivas M, Velicer WF, Redding C. Mediation analysis of decisional balance, sun avoidance and sunscreen use in the precontemplation and preparation stages for sun protection. Psychol Health 2015; 30:1433-49. [PMID: 26040293 DOI: 10.1080/08870446.2015.1056791] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Mediation analyses of sun protection were conducted testing structural equation models using longitudinal data with three waves. An effect was said to be mediated if the standardised path between processes of change, decisional balance and sun protection outcomes was significant. DESIGN Longitudinal models of sun protection using data from individuals in the precontemplation (N = 964) and preparation (N = 463) stages who participated of an expert system intervention. MAIN OUTCOME MEASURES Nine processes of change for sun protection, decisional balance constructs of sun protection (pros and cons), sun avoidance behaviour and sunscreen use. RESULTS With the exception of two processes in the preparation stage, processes of change predicted the pros (r = .126-.614), and the pros predicted the outcomes (r = .181-.272). Three models with the cons as mediator in the preparation stage, and none in the precontemplation stage, showed a mediated relationship between processes and outcomes. CONCLUSION In general, mediation analyses found both the process of change-to-pros and pros-to-behaviour paths significant for both precontemplation and preparation stages, and for both sun avoidance and sunscreen use outcomes. Findings provide support for the importance of assessing the role of underlying risk cognitions in improving sun protection adherence.
Collapse
Affiliation(s)
- Marimer Santiago-Rivas
- a Department of Oncological Sciences , Icahn School of Medicine at Mount Sinai , New York , NY , USA
| | - Wayne F Velicer
- b Cancer Prevention Research Center , University of Rhode Island , Kingston , RI , USA
| | - Colleen Redding
- b Cancer Prevention Research Center , University of Rhode Island , Kingston , RI , USA
| |
Collapse
|
7
|
Del Rosso JQ, Kircik L, Goldenberg G, Brian B. Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach. THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY 2014; 7:S2-S12. [PMID: 25302088 PMCID: PMC4187997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- James Q Del Rosso
- Dr. Del Rosso is an investigator, consultant, and speaker for LEO Pharma Inc. and a consultant and speaker for Valeant Pharmaceuticals and Ferndale Laboratories. Dr. Kircik is an investigator, consultant, and speaker for LEO Pharma Inc. and has served as an investigator, consultant, and/or speaker for Dusa, Ferndale, and Valeant. Dr. Goldenberg is a speaker and consultant for and provides research support for LEO Pharma Inc., Valeant, and PharmaDerm. Dr. Berman served on advisory boards of Graceway Pharmaceuticals, LEO Pharma Inc., Medicis, and PharmaDerm; as a consultant for Graceway Pharmaceuticals, Medicis, Dusa, Valeant, and LEO Pharma Inc.; as a speaker for LEO Pharma Inc., Medicis, PharmaDerm, Valeant, and Dusa; and as an investigator for LEO Pharma, Medicis, and Dusa
| | - Leon Kircik
- Dr. Del Rosso is an investigator, consultant, and speaker for LEO Pharma Inc. and a consultant and speaker for Valeant Pharmaceuticals and Ferndale Laboratories. Dr. Kircik is an investigator, consultant, and speaker for LEO Pharma Inc. and has served as an investigator, consultant, and/or speaker for Dusa, Ferndale, and Valeant. Dr. Goldenberg is a speaker and consultant for and provides research support for LEO Pharma Inc., Valeant, and PharmaDerm. Dr. Berman served on advisory boards of Graceway Pharmaceuticals, LEO Pharma Inc., Medicis, and PharmaDerm; as a consultant for Graceway Pharmaceuticals, Medicis, Dusa, Valeant, and LEO Pharma Inc.; as a speaker for LEO Pharma Inc., Medicis, PharmaDerm, Valeant, and Dusa; and as an investigator for LEO Pharma, Medicis, and Dusa
| | - Gary Goldenberg
- Dr. Del Rosso is an investigator, consultant, and speaker for LEO Pharma Inc. and a consultant and speaker for Valeant Pharmaceuticals and Ferndale Laboratories. Dr. Kircik is an investigator, consultant, and speaker for LEO Pharma Inc. and has served as an investigator, consultant, and/or speaker for Dusa, Ferndale, and Valeant. Dr. Goldenberg is a speaker and consultant for and provides research support for LEO Pharma Inc., Valeant, and PharmaDerm. Dr. Berman served on advisory boards of Graceway Pharmaceuticals, LEO Pharma Inc., Medicis, and PharmaDerm; as a consultant for Graceway Pharmaceuticals, Medicis, Dusa, Valeant, and LEO Pharma Inc.; as a speaker for LEO Pharma Inc., Medicis, PharmaDerm, Valeant, and Dusa; and as an investigator for LEO Pharma, Medicis, and Dusa
| | - Berman Brian
- Dr. Del Rosso is an investigator, consultant, and speaker for LEO Pharma Inc. and a consultant and speaker for Valeant Pharmaceuticals and Ferndale Laboratories. Dr. Kircik is an investigator, consultant, and speaker for LEO Pharma Inc. and has served as an investigator, consultant, and/or speaker for Dusa, Ferndale, and Valeant. Dr. Goldenberg is a speaker and consultant for and provides research support for LEO Pharma Inc., Valeant, and PharmaDerm. Dr. Berman served on advisory boards of Graceway Pharmaceuticals, LEO Pharma Inc., Medicis, and PharmaDerm; as a consultant for Graceway Pharmaceuticals, Medicis, Dusa, Valeant, and LEO Pharma Inc.; as a speaker for LEO Pharma Inc., Medicis, PharmaDerm, Valeant, and Dusa; and as an investigator for LEO Pharma, Medicis, and Dusa
| |
Collapse
|